These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 9447502)

  • 21. Heterogeneity of Treatment Response to Citalopram for Patients With Alzheimer's Disease With Aggression or Agitation: The CitAD Randomized Clinical Trial.
    Schneider LS; Frangakis C; Drye LT; Devanand DP; Marano CM; Mintzer J; Mulsant BH; Munro CA; Newell JA; Pawluczyk S; Pelton G; Pollock BG; Porsteinsson AP; Rabins PV; Rein L; Rosenberg PB; Shade D; Weintraub D; Yesavage J; Lyketsos CG;
    Am J Psychiatry; 2016 May; 173(5):465-72. PubMed ID: 26771737
    [TBL] [Abstract][Full Text] [Related]  

  • 22. No long-term effect of behavioral treatment on psychotropic drug use for agitation in Alzheimer's disease patients.
    Weiner MF; Tractenberg RE; Sano M; Logsdon R; Teri L; Galasko D; Gamst A; Thomas R; Thal LJ
    J Geriatr Psychiatry Neurol; 2002; 15(2):95-8. PubMed ID: 12083600
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of risperidone oral solution and intramuscular haloperidol with the latter shifting to oral therapy for the treatment of acute agitation in patients with schizophrenia.
    Fang M; Chen H; Li LH; Wu R; Li Y; Liu L; Ye M; Huang J; Zhu S; Wang G; Zhang Q; Zheng H; Zhang L; Wang B; Zhou J; Zhao JP
    Int Clin Psychopharmacol; 2012 Mar; 27(2):107-13. PubMed ID: 22233697
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neuroleptic malignant syndrome and cardiac surgery. A case report.
    Sirois F
    J Cardiovasc Surg (Torino); 2008 Oct; 49(5):695-6. PubMed ID: 18670390
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treating agitation and aggression in patients with Alzheimer's disease with escitalopram.
    Žmuc Veranič L; Pregelj P; Jerin A
    Psychogeriatrics; 2016 Nov; 16(6):384-385. PubMed ID: 26551073
    [No Abstract]   [Full Text] [Related]  

  • 26. Treatment of agitation in AD: a randomized, placebo-controlled clinical trial.
    Teri L; Logsdon RG; Peskind E; Raskind M; Weiner MF; Tractenberg RE; Foster NL; Schneider LS; Sano M; Whitehouse P; Tariot P; Mellow AM; Auchus AP; Grundman M; Thomas RG; Schafer K; Thal LJ;
    Neurology; 2000 Nov; 55(9):1271-8. PubMed ID: 11087767
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Double-blind pilot trial of desipramine versus fluoxetine in panic patients.
    Bystritsky A; Rosen RM; Murphy KJ; Bohn P; Keys SA; Vapnik T
    Anxiety; 1994-1995; 1(6):287-90. PubMed ID: 9160589
    [No Abstract]   [Full Text] [Related]  

  • 28. A double-blind randomized placebo-controlled withdrawal trial comparing memantine and antipsychotics for the long-term treatment of function and neuropsychiatric symptoms in people with Alzheimer's disease (MAIN-AD).
    Ballard C; Thomas A; Gerry S; Yu LM; Aarsland D; Merritt C; Corbett A; Davison C; Sharma N; Khan Z; Creese B; Loughlin P; Bannister C; Burns A; Win SN; Walker Z;
    J Am Med Dir Assoc; 2015 Apr; 16(4):316-22. PubMed ID: 25523285
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Changes in QTc interval in the citalopram for agitation in Alzheimer's disease (CitAD) randomized trial.
    Drye LT; Spragg D; Devanand DP; Frangakis C; Marano C; Meinert CL; Mintzer JE; Munro CA; Pelton G; Pollock BG; Porsteinsson AP; Rabins PV; Rosenberg PB; Schneider LS; Shade DM; Weintraub D; Yesavage J; Lyketsos CG;
    PLoS One; 2014; 9(6):e98426. PubMed ID: 24914549
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neuroleptic strategies for terminal agitation in patients with cancer and delirium at an acute palliative care unit: a single-centre, double-blind, parallel-group, randomised trial.
    Hui D; De La Rosa A; Wilson A; Nguyen T; Wu J; Delgado-Guay M; Azhar A; Arthur J; Epner D; Haider A; De La Cruz M; Heung Y; Tanco K; Dalal S; Reddy A; Williams J; Amin S; Armstrong TS; Breitbart W; Bruera E
    Lancet Oncol; 2020 Jul; 21(7):989-998. PubMed ID: 32479786
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Management of agitation and aggression associated with Alzheimer's disease: controversies and possible solutions.
    Ballard C; Corbett A; Chitramohan R; Aarsland D
    Curr Opin Psychiatry; 2009 Nov; 22(6):532-40. PubMed ID: 19696673
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined treatment with haloperidol and trazodone in patients with tic disorders.
    Saccomani L; Rizzo P; Nobili L
    J Child Adolesc Psychopharmacol; 2000; 10(4):307-10. PubMed ID: 11191691
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is anxious-agitated major depression responsive to fluoxetine? A double-blind comparison with amitriptyline.
    Marchesi C; Ceccherininelli A; Rossi A; Maggini C
    Pharmacopsychiatry; 1998 Nov; 31(6):216-21. PubMed ID: 9930635
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness of fluoxetine and doxepin in treatment of melancholia in depressed patients.
    Sandor P; Baker B; Irvine J; Dorian P; McKessok D; Mendlowitz S
    Depress Anxiety; 1998; 7(2):69-72. PubMed ID: 9614594
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Atypical antipsychotic medications in Alzheimer's disease: effectiveness versus expectations.
    Schultz SK
    Am J Psychiatry; 2008 Jul; 165(7):787-9. PubMed ID: 18593779
    [No Abstract]   [Full Text] [Related]  

  • 36. A Framework for Developing Pharmacotherapy for Agitation in Alzheimer's Disease: Recommendations of the ISCTM* Working Group.
    O'Gorman C; Khoury R; Anderson A; Carter M; DiCesare F; Dubé S; Ereshefsky L; Grossberg G; Hefting N; Khan S; Lind S; Moebius H; Shiovitz T; Rosenberg P
    J Prev Alzheimers Dis; 2020; 7(4):274-282. PubMed ID: 32920630
    [No Abstract]   [Full Text] [Related]  

  • 37. The use of risperidone for psychosis and agitation in demented patients with Parkinson's disease.
    Workman RH; Orengo CA; Bakey AA; Molinari VA; Kunik ME
    J Neuropsychiatry Clin Neurosci; 1997; 9(4):594-7. PubMed ID: 9447503
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone.
    De Deyn PP; Katz IR; Brodaty H; Lyons B; Greenspan A; Burns A
    Clin Neurol Neurosurg; 2005 Oct; 107(6):497-508. PubMed ID: 15922506
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multiple medication use presenting as Parkinson's dementia complex: a message from Titanic.
    Preskorn SH
    J Psychiatr Pract; 2008 Jan; 14(1):45-54. PubMed ID: 18212602
    [No Abstract]   [Full Text] [Related]  

  • 40. Open trial study of a combined antidepressant (amitryptiline, perphenazine, diazepam) versus fluoxetine or imipramine in ambulatory depressed patients.
    Diaz A; Fouilloux C; Ortiz S
    Proc West Pharmacol Soc; 2002; 45():154-5. PubMed ID: 12434564
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.